Showing 25 to 36 of 171 results
mRNA-Based Immunotherapy Shows Promise, Potentially Lowering CAR-T Therapy Costs
A new mRNA-based immunotherapy treatment, developed by Carl June and colleagues at the University of Pennsylvania and Capstan, shows promise in treating autoimmune diseases and leukemia in preclinical trials, potentially lowering the cost to around €5,000 per dose.
mRNA-Based Immunotherapy Shows Promise, Potentially Lowering CAR-T Therapy Costs
A new mRNA-based immunotherapy treatment, developed by Carl June and colleagues at the University of Pennsylvania and Capstan, shows promise in treating autoimmune diseases and leukemia in preclinical trials, potentially lowering the cost to around €5,000 per dose.
Progress
48% Bias Score
BioNTech to Acquire Curevac for $1.25 Billion
BioNTech, co-founded by Prof. Ugur Sahin and Prof. Ozlem Tureci, will acquire Curevac for $1.25 billion, strengthening its mRNA cancer treatments, with the deal expected to close by late 2025, combining their expertise in mRNA technology.
BioNTech to Acquire Curevac for $1.25 Billion
BioNTech, co-founded by Prof. Ugur Sahin and Prof. Ozlem Tureci, will acquire Curevac for $1.25 billion, strengthening its mRNA cancer treatments, with the deal expected to close by late 2025, combining their expertise in mRNA technology.
Progress
32% Bias Score
NHS to Expand Robotic Surgery to Cut Waiting Lists
The NHS in England plans to increase robot-assisted surgeries from 70,000 to 500,000 annually by 2035, aiming to reduce waiting times and improve patient outcomes by using this technology for cancer treatment, hysterectomies, joint replacements, and emergencies; however, significant capital funding ...
NHS to Expand Robotic Surgery to Cut Waiting Lists
The NHS in England plans to increase robot-assisted surgeries from 70,000 to 500,000 annually by 2035, aiming to reduce waiting times and improve patient outcomes by using this technology for cancer treatment, hysterectomies, joint replacements, and emergencies; however, significant capital funding ...
Progress
40% Bias Score
Alternative Cancer Remedies: Limited Evidence and Potential Risks
Professor Dr. Uta Hübner from Jena University Clinic cautions against using alternative remedies like turmeric and mistletoe alongside conventional cancer treatments due to limited evidence of effectiveness and potential interactions, stressing the importance of a healthy diet.
Alternative Cancer Remedies: Limited Evidence and Potential Risks
Professor Dr. Uta Hübner from Jena University Clinic cautions against using alternative remedies like turmeric and mistletoe alongside conventional cancer treatments due to limited evidence of effectiveness and potential interactions, stressing the importance of a healthy diet.
Progress
56% Bias Score
Rising Lung Cancer in Never-Smokers: Genetic and Environmental Factors
Lung cancer diagnoses are rising among never-smokers, linked to genetic mutations (like EGFR) and environmental factors such as air pollution (PM2.5) and radon, affecting women disproportionately, especially Asian women, despite decreasing smoking rates.
Rising Lung Cancer in Never-Smokers: Genetic and Environmental Factors
Lung cancer diagnoses are rising among never-smokers, linked to genetic mutations (like EGFR) and environmental factors such as air pollution (PM2.5) and radon, affecting women disproportionately, especially Asian women, despite decreasing smoking rates.
Progress
52% Bias Score
25 Years of Cancer Research at CIC: Extending Lives and Transforming Treatments
The Centro de Investigación del Cáncer (CIC) in Salamanca, Spain, celebrates 25 years of cancer research, significantly improving survival rates for multiple myeloma and other cancers through advancements in treatments and a focus on understanding intercellular communication within tumors.
25 Years of Cancer Research at CIC: Extending Lives and Transforming Treatments
The Centro de Investigación del Cáncer (CIC) in Salamanca, Spain, celebrates 25 years of cancer research, significantly improving survival rates for multiple myeloma and other cancers through advancements in treatments and a focus on understanding intercellular communication within tumors.
Progress
48% Bias Score
New Light-Based Cancer Treatment Shows Promise
Texas researchers have developed a new cancer treatment using infrared light and a synthetic blue dye to destroy cancer cells with 99% efficiency in lab cultures; the method, called vibronic-driven action, is currently undergoing further testing and hopes to enter human trials within 5-7 years.
New Light-Based Cancer Treatment Shows Promise
Texas researchers have developed a new cancer treatment using infrared light and a synthetic blue dye to destroy cancer cells with 99% efficiency in lab cultures; the method, called vibronic-driven action, is currently undergoing further testing and hopes to enter human trials within 5-7 years.
Progress
60% Bias Score
Rome Oncology Conference: Integrating Care and Precision Medicine
A two-day oncology conference in Rome (June 13-14) will focus on integrating hospital and territorial care and precision medicine to improve cancer treatment and patient outcomes in Italy, aligning with the National Recovery and Resilience Plan (PNRR).
Rome Oncology Conference: Integrating Care and Precision Medicine
A two-day oncology conference in Rome (June 13-14) will focus on integrating hospital and territorial care and precision medicine to improve cancer treatment and patient outcomes in Italy, aligning with the National Recovery and Resilience Plan (PNRR).
Progress
44% Bias Score
Argentine Hospital Uses Puppetry to Empower Cancer Patients
A hospital in Córdoba, Argentina, uses a weekly puppetry program to help 20 cancer patients cope with their illness by creating and performing short plays, improving their emotional well-being and fostering a sense of community.
Argentine Hospital Uses Puppetry to Empower Cancer Patients
A hospital in Córdoba, Argentina, uses a weekly puppetry program to help 20 cancer patients cope with their illness by creating and performing short plays, improving their emotional well-being and fostering a sense of community.
Progress
24% Bias Score
Immunotherapy Shows Promise in Treating Cutaneous Squamous Cell Carcinoma
An Australian clinical trial demonstrates that a new immunotherapy using genetically modified antibodies significantly reduces recurrence of cutaneous squamous cell carcinoma (CSCC), offering a potential cure for this common, often deadly, cancer. The 24-month disease-free rate in the treatment arm ...
Immunotherapy Shows Promise in Treating Cutaneous Squamous Cell Carcinoma
An Australian clinical trial demonstrates that a new immunotherapy using genetically modified antibodies significantly reduces recurrence of cutaneous squamous cell carcinoma (CSCC), offering a potential cure for this common, often deadly, cancer. The 24-month disease-free rate in the treatment arm ...
Progress
44% Bias Score
AI: Revolutionizing Cancer Care Affordability and Outcomes
AI is revolutionizing cancer care, lowering costs and improving survival. Early detection tools, like those used at The Christ Hospital, increase early diagnoses. Personalized treatments, such as ArteraAI's Prostate Test, reduce unnecessary therapies. AI-powered surgery and infection monitoring (Tem...
AI: Revolutionizing Cancer Care Affordability and Outcomes
AI is revolutionizing cancer care, lowering costs and improving survival. Early detection tools, like those used at The Christ Hospital, increase early diagnoses. Personalized treatments, such as ArteraAI's Prostate Test, reduce unnecessary therapies. AI-powered surgery and infection monitoring (Tem...
Progress
40% Bias Score
Liquid Biopsy Shows Promise for Early Detection and Prevention of Breast Cancer Relapse
A new blood test, "liquid biopsy," detects breast cancer relapse earlier than traditional methods, allowing for preventive treatment with camizestrant, showing a 56% reduction in disease progression risk in a clinical trial involving 3000 patients.
Liquid Biopsy Shows Promise for Early Detection and Prevention of Breast Cancer Relapse
A new blood test, "liquid biopsy," detects breast cancer relapse earlier than traditional methods, allowing for preventive treatment with camizestrant, showing a 56% reduction in disease progression risk in a clinical trial involving 3000 patients.
Progress
48% Bias Score
Showing 25 to 36 of 171 results